Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tesetaxel with PD-(L)1 inhibitors or as monotherapy in advanced breast cancer
2018-004715-41Phase 2Terminated
- Sponsor
- Odonate Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tesetaxel in breast cancer and triple-negative breast cancer (TNBC) (4 arms), sponsored by Odonate Therapeutics. Primary endpoint: Primary efficacy endpoints. Started Sep 2019; status: terminated.
02
Drugs
tesetaxel
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-004715-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004715-41.